Jump to content
Sign in to follow this  

Dr. Drew Moghanaki joins LUNGevity Foundation Scientific Advisory Board

Recommended Posts

LUNGevity Foundation is proud to announce that Drew Moghanaki, MD, MPH, has joined its distinguished Scientific Advisory Board.

Dr. Moghanaki is a highly regarded expert in the field of radiation oncology and leads the Clinical Research program at Hunter Holmes McGuire Veterans Affairs Medical Center in Richmond, Virginia. Dr. Moghanaki has been instrumental in bringing more than $34 million in funding to improve outcomes for lung cancer patients through a phase III lung cancer trial for veterans and a key VA partnership to increase access to lung cancer screening.

LUNGevity’s Scientific Advisory Board oversees the Foundation’s scientific strategy and ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of all people diagnosed with lung cancer. LUNGevity’s awardees are working to improve our ability to detect, diagnose, and treat lung cancer, as well as prevent its recurrence. LUNGevity is the only lung cancer non-profit with a long-term, strategic focus on the early detection of lung cancer.

“We are thrilled to have Dr. Moghanaki join LUNGevity’s Scientific Advisory Board,” said Andrea Ferris, president of LUNGevity Foundation. “He brings expertise in radiation oncology as well as a deep knowledge of the VA healthcare system. We are excited to have his unique perspective and expertise to help guide our research program.”

Read the full press release here.Dr. Drew Moghanaki joins LUNGevity Foundation Scientific Advisory Board

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this